Cilostazol Now, or the Twelve-Week Wait for Supervised Exercise
A single patient for whom both guideline-endorsed first-line treatments for claudication are correct in principle, and only one of them is realistically reachable this month.
D.K., a 64-year-old man, spent thirty-one years delivering mail on foot before retiring last spring, and the irony of his current problem isn't lost on him — the same legs that carried him five miles a day for three decades now cramp hard enough after two blocks that he has to stop and wait it out before continuing. He first noticed it eight months ago, dismissed it as ordinary aging, and only brought it up when his daughter noticed him pausing outside stores on their weekly grocery trips.
He has hypertension, treated, and a thirty-pack-year smoking history, quit twelve years ago; no diabetes, no heart failure, no prior cardiac events. An ankle-brachial index came back at 0.68, confirming peripheral artery disease at a moderate severity consistent with his symptoms, and imaging shows focal disease without critical narrowing requiring urgent intervention. What complicates his case isn't the diagnosis — it's logistics. The nearest program offering supervised exercise therapy is forty-five minutes away, requires attendance three times a week for twelve weeks, and he stopped driving at night two years ago after a minor accident; getting there depends entirely on his daughter's schedule, which she's already stretched thin trying to accommodate.
Neither treatment is a stopgap for the other, clinically speaking — cilostazol works by inhibiting phosphodiesterase-3, increasing intracellular cyclic AMP in platelets and vascular smooth muscle to produce both a vasodilatory and mild antiplatelet effect, while supervised exercise improves walking distance through a mix of collateral vessel development, mitochondrial adaptation in ischemic muscle, and improved walking economy that a home program without structured coaching tends not to replicate as reliably. The two mechanisms don't compete for the same biological target, which is part of why combining them, rather than choosing between them, was always plausible once the scheduling problem was named directly.
Cilostazol now, exercise program in parallel
Supervised exercise therapy is the treatment I want him on. It's Class 1, Level A evidence — the same tier as cilostazol — and the benefit extends past his legs; it's a structured cardiovascular intervention for a man with a smoking history and hypertension, not just a walking-distance fix. I don't want to substitute a pill for that if there's any way to make the program actually reachable for him. Separately — he isn't on a statin, and symptomatic PAD carries a Class 1, Level A recommendation for high-intensity statin therapy aimed at a 50% or greater LDL reduction. That one isn't optional and isn't part of this debate.
The access problem is real, though, and it isn't a reason to leave him untreated for twelve weeks while a ride schedule gets sorted out. Cilostazol has the same top-tier evidence rating for the same indication, it isn't conditioned on anyone else's availability, and starting it today doesn't foreclose adding the exercise program once transportation is arranged. His only absolute contraindication to check is heart failure, and he doesn't have it.
I'm not proposing cilostazol instead of the program — I'm proposing it while the program gets arranged, since “wait twelve weeks for the ideal treatment” isn't actually free of cost for a man who's already restructuring his life around how far he can walk.
There's no real conflict here once you say it that way — start cilostazol now, confirmed against his echocardiogram showing preserved ejection fraction and no heart failure, and put in the supervised exercise referral today rather than waiting to see how the medication goes first. He doesn't have to choose between the two; the schedule was the only thing making it look like an either-or.
Started on cilostazol today, with the supervised exercise referral placed the same visit rather than sequenced after a medication trial. Follow-up in six weeks to assess both tolerance and walking distance.
It continues alongside the exercise program once transportation is arranged, rather than being stopped in favor of it.
The exercise program becomes the primary treatment, with cilostazol reduced or discontinued rather than pushed through poor tolerance.
Headache is the common one — it reaches roughly thirty percent of patients, and it is the single leading reason people stop the drug, though only about three or four percent discontinue for it outright, with palpitations and diarrhea near one percent each. The group discussed those numbers with him openly rather than treating them as a footnote, framing his six-week follow-up explicitly as a checkpoint, not a formality.